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Figure S30. Analysis of the 100 ns MD simulation of αβ-tubulin-4e complex. Root-mean-square deviation (RMSD) of 
(A) αβ-tubulin backbone and (B) 4e structure calculated from the least-square fit to the heterodimer. (C) Average and
(D) per amino acid number of H-bonds of 4i with the NZ/COL binding site through the simulation. (E) Depiction of
residues involved in the interaction of 4i with αβ-tubulin. The color scale shows the residues with the higher (red) to the
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